
Amsel Medical Corporation Profile last edited on: 8/16/2021
CAGE: 6PXF8
UEI: UUM9WLJWJQ24
Business Identifier: Permanent or temporary blood vessel occlusion Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.
Location Information
171 Hamilton Street Suie 212
Cambridge, MA 02139
Cambridge, MA 02139
(617) 395-8825 |
N/A |
www.amseltech.com~www.amselmedical.com/ |
Location: Single
Congr. District: 07
County: Middlesex
Congr. District: 07
County: Middlesex
Public Profile
Organized around the objective of extending the Golden Hour for survival - saving limbs and lives - Amsel Medical Corporation has developed and manufactures an occluder device designed to secure close blood vessels as well as tubular structures during open surgical procedures. The system is anchored in existing surgical clamping technology that helps blood vessels to heal faster with minimally invasive needle delivery. This results in secure occlusion similar to that of a transfixion suture and eliminates slippage, enabling medical professionals to treat venous reflux disease and occlude vessels of varying sizes, types, and wall thickness. The firm's trauma management and hemorrhage control solution - the SCureTO - is designed to reduce mortality rates while also minimizing limb loss. Junctional and non-compressible hemorrhage in the battlefield is responsible for greater than 60% mortality amongst US combatants and is also a major cause of mortality and morbidity for civilian trauma victims. As such there is need for a solution that rapidly and effectively controls blood loss to improve survival and minimize limb ischemia.
Extent of SBIR involvement
Synopsis: Awardee Business Condition
Employee Range
5-9Revenue Range
.5M-1MVC funded?
YesPublic/Private
Privately HeldStock Info
----IP Holdings
5-9Awards Distribution by Agency
Most Recent SBIR Projects
Year | Phase | Agency | Total Amount | |
---|---|---|---|---|
2022 | 2 | AF | $2,542,598 | |
Project Title: Open Call for Innovative Defense-Related Dual-Purpose Technologies/Solutions with a Clear Air Force Stakeholder Need |
Key People / Management
David Doster -- Chief Executive Officer
Arnold Miller -- Co-Founder, Chief Medical Officer,President and Board Member
Joseph Gerardi -- Chief Financial Officer
Raanan Miller -- Co-Founder, Chief Technology Officer
Daniel Recinella -- VP, Research & Development
Arnold Miller -- Co-Founder, Chief Medical Officer,President and Board Member
Joseph Gerardi -- Chief Financial Officer
Raanan Miller -- Co-Founder, Chief Technology Officer
Daniel Recinella -- VP, Research & Development
Company News
There are no news available.